Cancer BiologybioRxivPreprint
Targeting the hyperactive STAT3/5 pathway in cutaneous T-cell lymphoma with the multi-kinase nuclear transporter inhibitor IQDMA
Saptaswa Dey, Helena Sorger, Michaela Schlederer…·Peter Wolf
This study evaluates IQDMA, a multi-kinase inhibitor, as a targeted therapy for cutaneous T-cell lymphoma, showing significant tumor volume reduction and STAT3/5 pathway inhibition compared to PUVA.
DOI 10.1101/2025.03.03.641168